Molecular structure of SB 265610, CAS Number: 211096-49-0
SB 265610 (CAS 211096-49-0)
Alternate Names:
N-(2-Bromophenyl)-N′-(7-cyano-1H-benzotriazol-4-yl)urea
Application:
SB 265610 is a potent CXCR2 antagonist
CAS Number:
211096-49-0
Purity:
≥99%
Molecular Weight:
357.16
Molecular Formula:
C14H9BrN6O
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
SB 265610 is a benzotriazole derivative shown to act as a potent CXCR2 antagonist that inhibits CINC-1-mediated but not C5a-mediated Ca2+ mobilization with IC50 values of 3.4 and 6800 nM respectively. It has also been shown to inhibit CINC-induced chemotaxis and attenuate neutrophil accumulation in inflammatory lung injury in vivo.
SB 265610 (CAS 211096-49-0) References
- Nonpeptide CXCR2 antagonist prevents neutrophil accumulation in hyperoxia-exposed newborn rats. | Auten, RL., et al. 2001. J Pharmacol Exp Ther. 299: 90-5. PMID: 11561067
- CXCR2 blockade reduces radical formation in hyperoxia-exposed newborn rat lung. | Liao, L., et al. 2006. Pediatr Res. 60: 299-303. PMID: 16923948
- Nonpeptidergic allosteric antagonists differentially bind to the CXCR2 chemokine receptor. | de Kruijf, P., et al. 2009. J Pharmacol Exp Ther. 329: 783-90. PMID: 19190236
- SB265610 is an allosteric, inverse agonist at the human CXCR2 receptor. | Bradley, ME., et al. 2009. Br J Pharmacol. 158: 328-38. PMID: 19422399
- A common intracellular allosteric binding site for antagonists of the CXCR2 receptor. | Salchow, K., et al. 2010. Br J Pharmacol. 159: 1429-39. PMID: 20233217
- Virus-infected alveolar epithelial cells direct neutrophil chemotaxis and inhibit their apoptosis. | Rzepka, JP., et al. 2012. Am J Respir Cell Mol Biol. 46: 833-41. PMID: 22312020
- Molecular mechanisms of the antitumor activity of SB225002: a novel microtubule inhibitor. | Goda, AE., et al. 2013. Biochem Pharmacol. 85: 1741-52. PMID: 23611835
- Rho-kinase inhibitor prevents bleomycin-induced injury in neonatal rats independent of effects on lung inflammation. | Lee, AH., et al. 2014. Am J Respir Cell Mol Biol. 50: 61-73. PMID: 23947621
- Combined anti CXC receptors 1 and 2 therapy is a promising anti-inflammatory treatment for respiratory diseases by reducing neutrophil migration and activation. | Planagumà, A., et al. 2015. Pulm Pharmacol Ther. 34: 37-45. PMID: 26271598
- Chemokine (C-X-C motif) receptor 2 blockade by SB265610 inhibited angiotensin II-induced abdominal aortic aneurysm in Apo E-/- mice. | Nie, H., et al. 2019. Heart Vessels. 34: 875-882. PMID: 30535755
- Discovery, structure-activity relationship study and biological evaluation of 2-thioureidothiophene-3-carboxylates as a novel class of C-X-C chemokine receptor 2 (CXCR2) antagonists. | Xue, D., et al. 2020. Eur J Med Chem. 204: 112387. PMID: 32829163
- Taxane-induced Attenuation of the CXCR2/BCL-2 Axis Sensitizes Prostate Cancer to Platinum-based Treatment. | Ruiz de Porras, V., et al. 2021. Eur Urol. 79: 722-733. PMID: 33153817
- METTL3 Inhibits Antitumor Immunity by Targeting m6A-BHLHE41-CXCL1/CXCR2 Axis to Promote Colorectal Cancer. | Chen, H., et al. 2022. Gastroenterology. 163: 891-907. PMID: 35700773
Inhibitor of:
CXCR-7, fractalkine, IL-8RB, Integrin β5, K-cadherin, and S-100A5.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
SB 265610, 1 mg | sc-361341 | 1 mg | $81.00 | |||
SB 265610, 10 mg | sc-361341A | 10 mg | $209.00 |